AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

Sitara-M IR 50/500 Tablet

Prescription Icon
Prescription Required

Marketer

Intas Pharmaceuticals Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Sitara-M IR 50/500 Tablet

Duo-Med IR 50/500 tablets combine two medications to manage elevated blood glucose in type 2 diabetes. This dual action helps prevent severe diabetic complications like renal failure and vision loss, potentially lowering heart attack and stroke risk. Duo-Med IR 50/500 may be used independently or with other antidiabetic agents, maximizing effectiveness when paired with a balanced diet and consistent exercise. Dosage is personalized based on your health status, glucose levels, and current medications. Ingesting it with food minimizes stomach upset. Consistent daily dosing at the same time is crucial for optimal results; discontinuation requires your physician's approval. Adherence to your prescribed diet and exercise plan is vital for diabetes control. Common side effects include nausea, vomiting, diarrhea, abdominal discomfort, headache, and pharyngitis. Hypoglycemia is a potential side effect, especially with concurrent use of insulin or sulfonylureas; learn to identify and manage this complication. This medication isn't for everyone. Inform your doctor of any pre-existing kidney, liver, or heart conditions, pancreatic issues, or significant alcohol consumption before use. Pregnant or lactating individuals should consult their physician. Interactions with other medications are possible; disclose all medications to your doctor to ensure safety. Alcohol should be limited due to its hypoglycemic effects. Your doctor will monitor your renal function and blood sugar levels throughout treatment.

Primary Ingredients of Sitara-M IR 50/500 Tablet

No text provided to rephrase.

Uses of Sitara-M IR 50/500 Tablet

Managing type 2 diabetes

Major Benefits of Sitara-M IR 50/500 Tablet:

Consume this medication precisely as your physician directs, adhering to the prescribed dosage and timeframe. Ingest the Sitara-M IR 50/500 Tablet whole; avoid chewing, crushing, or fracturing it. Administer this medication with a meal.

Common Side effects of Sitara-M IR 50/500 Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Sitara-M IR 50/500 Tablet:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the Sitara-M IR 50/500 Tablet whole; avoid chewing, crushing, or fracturing it. Administer this medication with a meal.

How Sitara-M IR 50/500 Tablet works:

Sitara-M IR 50/500 tablets contain sitagliptin and metformin, working synergistically to manage blood glucose. Sitagliptin boosts insulin production by the pancreas, enhances insulin utilization, and diminishes hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and improves insulin sensitivity. This dual action leads to superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol alongside Sitara-M IR 50/500 Tablet is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Sitara-M IR 50/500 Tablet during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Sitara-M IR 50/500 tablets while breastfeeding is likely inadvisable. Available human data indicates a potential for the medication to transfer to breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving may be impaired by excessively low or high blood sugar levels. Refrain from driving if such symptoms arise.

KidneyKidneyCAUTION

Patients with kidney impairment should use Sitara-M IR 50/500 Tablets cautiously, potentially requiring dosage modification. Consult your physician. Avoid Sitara-M IR 50/500 Tablets if you have severe kidney disease. Regular kidney function monitoring is recommended during treatment.

LiverLiverUNSAFE

The use of Sitara-M IR 50/500 Tablet is contraindicated in individuals with hepatic impairment and should be strictly avoided. Medical advice is recommended.

What if you forget to take Sitara-M IR 50/500 Tablet :

Should you forget a Sitara-M IR 50/500 Tablet dose, administer it immediately. Nevertheless, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Sitara-M IR 50/500 Tablet

LabelValue
Developing Habits No.
Type of Treatment Diabetes Management

FAQs on Sitara-M IR 50/500 Tablet

Sitara-M IR 50/500 Tablet combines sitagliptin and metformin to treat type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Prolonged Sitara-M IR 50/500 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Sitara-M IR 50/500 Tablet may cause common side effects including hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory tract infections. Rare but serious side effects such as lactic acidosis may occur. Prolonged use can also result in vitamin B12 deficiency.
Sitara-M IR 50/500 Tablet is contraindicated in patients with allergies to its components or excipients, and those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitara-M IR 50/500 tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication; ensure it remains inaccessible to children, pets, and others.
Sitara-M IR 50/500 Tablet use can cause lactic acidosis, a serious medical emergency resulting from excessive blood lactic acid (also called MALA, or Metformin-associated lactic acidosis). This rare side effect is why the medication is avoided in patients with kidney disease, the elderly, or those who consume large amounts of alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, stop taking Sitagliptin + Metformin and seek immediate medical attention.
Sitara-M IR 50/500 Tablet combines sitagliptin and metformin to treat type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Sitara-M IR 50/500 Tablet may cause common side effects including low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects such as lactic acidosis are possible. Prolonged use may result in vitamin B12 deficiency.
Sitara-M IR 50/500 Tablet is contraindicated in patients with allergies to its components or excipients, and those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining alcohol and Sitara-M IR 50/500 tablets is unsafe due to an increased risk of lactic acidosis.
Sitara-M IR 50/500 Tablet (containing metformin) can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA, or Metformin-Associated Lactic Acidosis). This rare side effect necessitates avoiding its use in patients with kidney disease, the elderly, or those who consume large amounts of alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these symptoms, discontinue Sitagliptin + Metformin immediately and seek medical attention.
Prolonged Sitara-M IR 50/500 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left untreated. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Dispose of any unused medication safely and ensure it remains inaccessible to children, pets, and others.
Sitara-M IR 50/500 Tablet combines sitagliptin and metformin to treat type 2 diabetes mellitus in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Sitara-M IR 50/500 Tablet may cause common side effects such as hypoglycemia, taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Sitara-M IR 50/500 Tablet is contraindicated in patients with allergies to its components or excipients, and those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitara-M IR 50/500 Tablet with alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitara-M IR 50/500 Tablet use can cause lactic acidosis (MALA, or Metformin-associated lactic acidosis), a serious medical emergency resulting from excessive blood lactic acid. This rare side effect necessitates caution in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If these occur, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Sitara-M IR 50/500 Tablet use can lead to vitamin B12 deficiency by impairing its absorption. This deficiency, if left untreated, may result in anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness), urinary issues, cognitive changes, and ataxia. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and ensure it remains inaccessible to children, pets, and others.
Sitara-M IR 50/500 Tablet
82
MRP 95
13% off